DILH
NBIX icon

Dai-ichi Life Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Dai-ichi Life Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24,894
Closed -$1.26M – 309
2016
Q3 		$1.26M Buy
+24,894
New +$1.24M 0.04% 370

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dai-ichi Life Holdings's NBIX Position: Q4 2016 in Review

Dai-ichi Life Holdings sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 24,894 shares — an estimated $1.26M sold.

Dai-ichi Life Holdings first reported a position in NBIX in Q3 2016 and held it in 1 quarter. The position peaked at $1.26M in Q3 2016. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • Dai-ichi Life Holdings reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
  • Dai-ichi Life Holdings sold 24,894 Neurocrine Biosciences shares in Q4 2016, an estimated $1.26M.
  • Dai-ichi Life Holdings first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 1 quarter.
  • Dai-ichi Life Holdings's Neurocrine Biosciences position peaked at $1.26M in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Dai-ichi Life Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.